With the emergence of megarounds in the past year, company leaders are wondering about the prospects for funding if their R&D is not in the most sought after therapeutic areas. Is it still possible to receive fewer dollars to support advancement to the next milestone? What do investors need to see to fund new companies? How can biotech executives stand out in this competitive field? This session will begin with a presentation from the HSBC Innovation Banking 2024 annual report summarizing trends. After the overview, investors and executives will provide insight on venture financing opportunities for the year ahead, perspective on pitfalls to avoid, and considerations in a dynamic landscape. ​